User profiles for Jennifer Vidler

Jennifer Vidler

Verified email at nhs.net
Cited by 1687

[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …

…, R Graham, J Cooper, M Khan, J Vidler… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with
cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (…

Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5‐year experience

JB Vidler, K Gardner, K Amenyah… - British journal of …, 2015 - Wiley Online Library
Delayed haemolytic transfusion reactions (DHTR) are potentially life‐threatening complications
in patients with sickle cell disease (SCD). Between 1 August 2008 and 31 December …

[PDF][PDF] Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

…, T Ng, J Spicer, M Van Hemelrijck, M Kumar, J Vidler… - Cancer cell, 2021 - cell.com
Given the immune system's importance for cancer surveillance and treatment, we have
investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some …

[HTML][HTML] Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience

V Shah, TK Ko, M Zuckerman, J Vidler… - British Journal of …, 2020 - ncbi.nlm.nih.gov
2. Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost.
2020. https://doi. org/10.1111/jth. 14879 3. Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, …

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority …

…, R Graham, J Cooper, M Khan, J Vidler… - MedRxiv, 2021 - medrxiv.org
Background The efficacy and safety profile of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in …

[PDF][PDF] Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer

…, C Gousis, C Domingo-Vila, J Cooper, J Vidler… - Cancer Cell, 2021 - cell.com
Patients with cancer are considered to be at high-risk for SARS-CoV-2 infection and severe
COVID-19 (Bakouny et al., 2020). Our ‘‘SOAP-02’’(Sars-CoV-2 fOr cAncer Patients) study …

[HTML][HTML] Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

…, GK Dimitraidis, S Gogoi, J Vidler… - The Lancet …, 2023 - thelancet.com
Background From early in the COVID-19 pandemic, evidence suggested a role for cytokine
dysregulation and complement activation in severe disease. In the TACTIC-R trial, we …

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

RJ Kelly, M Holt, J Vidler, LM Arnold, J Large, B Forrest… - Blood, 2024 - ashpublications.org
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder
that occurs on a background of bone marrow failure (BMF). In PNH, chronic intravascular …

Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study

…, D Halperin, T Worth, J Vidler… - British Journal of …, 2023 - Wiley Online Library
This retrospective, observational study evaluated patterns of inpatient versus outpatient tumour
lysis syndrome (TLS) monitoring during venetoclax ramp‐up in 170 patients with chronic …

[HTML][HTML] Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent …

J Vidler, C Rogers, D Yallop, S Devereux… - Journal of clinical & …, 2017 - Elsevier
High dose steroids (HDS) are used in the treatment of haematological malignancies. The
reported risk of steroid-induced diabetes (SID) is high. However, screening is not consistently …